• Abhi Mishra, Bhupesh Kumar, Vikas Dutta, V K Arya, and Anand Kumar Mishra.
• Department of Anaesthesia and Intensive Care, Chandigarh, India.
• J. Cardiothorac. Vasc. Anesth. 2016 Jun 1; 30 (3): 639-46.

ObjectiveTo compare the effects of levosimendan with milrinone in cardiac surgical patients with pulmonary hypertension and left ventricular dysfunction.DesignA prospective, randomized study.SettingTertiary care teaching hospital.ParticipantsThe study included patients with valvular heart disease and pulmonary artery hypertension undergoing valve surgery.InterventionsForty patients were allocated randomly to receive either milrinone, 50 µg/kg bolus followed by infusion at a rate of 0.5 µg/kg/min (group 1), or levosimendan, 10 µg/kg bolus followed by infusion at a rate of 0.1 µg/kg/min (group 2) for 24 hours after surgery.Measurements And Main ResultsHemodynamic parameters were measured using a pulmonary artery catheter, and biventricular functions were assessed using echocardiography. Mean pulmonary artery pressures and the pulmonary vascular resistance index were comparable between the 2 groups at several time points in the intensive care unit. Biventricular function was comparable between both groups. Postcardiopulmonary bypass right ventricular systolic and diastolic functions decreased in both groups compared with baseline, whereas 6 hours postbypass left ventricular ejection fraction improved in patients with stenotic valvular lesions. Levosimendan use was associated with higher heart rate, increased cardiac index, decreased systemic vascular resistance index, and increased requirement of norepinephrine infusion compared with milrinone.ConclusionsThe results of this study demonstrated that levosimendan was not clinically better than milrinone. Levosimendan therapy resulted in a greater increase in heart rate, decrease in systemic vascular resistance, and a greater need for norepinephrine than in patients who received milrinone.Copyright © 2016 Elsevier Inc. All rights reserved.

53 keywords...

hide…